Search

Transforming Growth Factor-B in Cancer Therapy, Volume II: Cancer Treatment and Therapy The chapters in this volume confer an abundance of knowledge about the current state ofour understanding oftransforming growth factor-B (TGF-B) in cancer treatment and therapy. Unlike several more traditional positive polypeptide growth factors that stim­ ulate cellular proliferation, the prototypical TGF-B is now known to inhibit the growth of most normal cell types, including those of epithelial and mesenchymal origin. However, there are examplesofcell types that can be stimulated by TGF-B under certain conditions. TGF-B also induces the accumulation of matrix molecules by stimulating their synthesis as well as inhibiting their degradation. Moreover, TGF-B induces apoptosis of certain cell types, thereby restricting their proliferation. OveractivityofTGF-~ has been linked to several diseases. For instance, the effect ofTGF-~ on matrix accumulation contributes to fibrotic conditions, like glomerulonephritis, lung fibrosis and liver cirrhosis (1). TGF-~ has a very complicated role in cancer that is only beginning to be understood.

Since the nineteenth century, when engineers were using nitroglycerin to blow up rockbeds, and doctors were prescribing it to relieve angina, scientists have been exploring the incredible and often baffling behavior of nitric oxide. In the 1980s, researchers discovered that nitric oxide had the capacity to regulate vascular tone through cyclic GMP,